Sun Pharma Q4 net up 23 percent, beats estimate
MUMBAI (Reuters) - Sun Pharmaceutical Industries(SUN.NS) reported a 23.4 percent rise in quarterly net profit beating market estimates, and India's top drugmaker by market value also announced a bonus share issue.
The Mumbai-based company said consolidated net profit rose to 10.12 billion rupees for the fourth quarter ended March 31, compared with 8.2 billion rupees a year earlier. Sales rose 31.8 percent to 30.71 billion rupees.
Analysts, on an average, had expected the company to post net profit of 9.07 billion rupees on net sales of 29.85 billion rupees, according to Thomson Reuters I/B/E/S.
The company also announced a one-for-one issue of bonus shares.
Shares of Sun Pharma, which has a market value of about $18.81 billion, fell 1.72 percent to 996.25 rupees on Tuesday, while the broader market gained 0.65 percent on the day. The stock has risen nearly 38 percent this year outperforming the benchmark index which has gained about 4 percent.
(Reporting by Kaustubh Kulkarni; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- Israel intensifies Gaza assault, Egyptians revise truce plan
- UPDATE 6-U.S. judge says cannot seize Kurdish crude for now
- UPDATE 2-EU agrees economic sanctions on Russia
- UPDATE 4-Obama says strains over Ukraine not leading to new Cold War with Russia
- Family of Texas doctor with Ebola not showing signs of virus
Top Indian mobile carrier Bharti Airtel posted a 61 percent rise in quarterly profit on Tuesday but fell short of analyst estimates as its African business continued to weigh. Full Article
Finmeccanica settles with Italy prosecutors to end Indian chopper deal probe. Full Article